Endometrial Cancer Clinical Trials (as of April 2019)

ENGOT-en9/A-AGO/LEAP-001

Leading group: A-AGO

Clinical Trial Study: A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Number of patients accrued: 0

Planned number of patients: 720

Participating groups:

TBA

 

 

ENGOT-en8/GINECO/ROCSAN

Leading group: GINECO

Clinical Trial Study: ROCSAN study: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy

Number of patients accrued: 0

Planned number of patients: 146

Participating groups:

AGO, GEICO, MITO

Planned start in 4Q 2018

 

 

ENGOT-en7/MaNGO/atTEdn

Leading group: MaNGO

Clinical Trial Study: AtTEdn trial: Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Number of patients accrued: 0

Planned number of patients: 550

Participating groups:

TBA

 

 

ENGOT-en6/NSGO/TSR-042

Leading group: NSGO

Clinical Trial Study: A phase III, randomized, open-label study of TSR-042, an Anti-PD-1 monoclonal antibody, versus investigator´s choice chemotherapy in patients with advanced/recurrent endometrial cancer

Number of patients accrued: 0

Planned number of patients: 520

Participating groups:

TBA

 

 

ENGOT-en5/BGOG-en5/SIENDO

Leading group: BGOG

Clinical Trial Study: A randomized phase III trial of maintenance with Selinexor/placebo after combination chemotherapy for patients with advanced or reccurent endometrial cancer

Number of patients accrued: 0

Planned number of patients: 161

Participating groups:

CEEGOG, GEICO, MITO, NOGGO

 

 

ENGOT-en4/NCRI/STATEC

Leading group: NCRI

Clinical Trial Study:

STATEC: A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer

Number of patients accrued: 7

Planned number of patients: 2000

Participating groups:

DGOG, (ANZGOG)

 

 

ENGOT-en3/NSGO/PALEO

Leading group: NSGO

Clinical Trial Study: A randomized phase II trial of Palbociclib in combination with letrozole versus letrozole for patients with oestrogen receptor positive recurrent endometrial cancer

Number of patients accrued: 33

Planned number of patients: 78

Participating groups:

GEICO, MITO, NOGGO

 

 

ENGOT-en2/NSGO/DGCG

Leading group: NSGO

Clinical Trial Study: Adjuvant chemotherapy in node negative endometrial carcinoma

Number of patients accrued: 195

Planned number of patients: 240

Participating groups:

BGOG, CEEGOG, EORTC, GEICO, ISGO, MaNGO, MITO, NOGGO

 

 

ENGOT-en1/NSGO/FANDANGO

Leading group: NSGO

Clinical Trial Study: A randomized phase II trial of first-line combination chemotherapy with Nintedanib/placebo for patients with advanced or recurrent endometrial cancer

Number of patients accrued: 86

Planned number of patients: 148

Participating groups:

BGOG, GINECO, NOGGO

 

 

 

Up Coming ENGOT Meeting

Vincci Soma Hotel, Madrid, Spain

October 17-18, 2019

Don't miss out on the latest updates

Save the Date!

You May Also Like

GCA6

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

background

CLINICAL TRIALS

Latest Published Research

 

Read More

patient2

FOR PATIENTS

Key Insights

 

Read More

Athens_logo

ESGO 2019 Congress

ESGO 2019 Athen Congress

 

Read More